33
Participants
Start Date
May 31, 2006
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2010
VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT
"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1~DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
National Health Research Institutes, Lymphoma Disease Committee, Taipei
Mackay Memorial Hospital
OTHER
National Cheng-Kung University Hospital
OTHER
Taichung Veterans General Hospital
OTHER
Taipei Veterans General Hospital, Taiwan
OTHER_GOV
Kaohsiung Veterans General Hospital.
OTHER
National Taiwan University Hospital
OTHER
Tri-Service General Hospital
OTHER
Chi Mei Medical Hospital
OTHER
Kaohsiung Medical University
OTHER
Changhua Christian Hospital
OTHER
Buddhist Tzu Chi General Hospital
OTHER
National Health Research Institutes, Taiwan
OTHER